A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, open-label, multicenter, dose-escalation study to evaluate the safety,
tolerability, pharmacokinetics (PK), and preliminary efficacy of ZN-c5 administered orally in
combination with abemaciclib (VERZENIO®) in participants with advanced estrogen-receptor
positive, human epidermal growth factor receptor-2 negative (ER+/HER2-) breast cancer.